MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
Lineage Cell Therapeutics DSO Ratio 2011-2026 | LCTX
Annual DSO Ratio Lineage Cell Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.2 | 26.6 | 91.1 | 4.85 K | 7.91 K | 0.8 | 2.49 K | 272 | 322 | 71.3 | 85.3 | 98.8 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.91 K | 0.8 | 1.35 K |
Quarterly DSO Ratio Lineage Cell Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.75 | 7.74 | 25.9 | - | 7.73 | 10.1 | 26 | - | 30.7 | 8.19 | 8.99 | - | 14.7 | 8.57 | 444 | 2.06 K | 42.6 | - | 28.2 | 62.2 | 19.3 | - | 3.91 | 1.62 | - | - | 2.51 | 3.07 | - | - | 9.05 | 6.71 | - | - | 40.2 | 14.2 | - | - | 16.6 | 49.5 | 23.9 | 26.1 | 41.7 | 30.1 | 42.1 | 45.3 | 48.1 | 31.5 | 73.6 | 43.2 | 72.1 | 33.8 | 35.9 | 34.9 | 52.3 | 19.7 | 28.2 | 21.3 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.06 K | 1.62 | 81.4 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Cerus Corporation
CERS
|
47 | $ 2.72 | 33.99 % | $ 518 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 21.95 | -2.23 % | $ 3.64 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
182 | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.71 | -1.16 % | $ 114 M | USA |
 |
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
60.8 | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Editas Medicine
EDIT
|
142 | $ 2.9 | -3.33 % | $ 257 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
56.5 | - | - | $ 2.02 B | USA |
 |
Edesa Biotech
EDSA
|
97.1 | $ 17.59 | -3.75 % | $ 56.2 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 2.93 | -8.15 % | $ 4.82 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
39.7 | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
157 | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.81 | 3.33 % | $ 27.9 M | Israel |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |